The Neuromyelitis Optica (Devic’s Syndrome) drugs in development market research report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Neuromyelitis Optica (Devic’s Syndrome). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and features dormant and discontinued products.
GlobalData tracks 48 drugs in development for Neuromyelitis Optica (Devic’s Syndrome) by 45 companies/universities/institutes. The top development phase for Neuromyelitis Optica (Devic’s Syndrome) is preclinical with 16 drugs in that stage. The Neuromyelitis Optica (Devic’s Syndrome) pipeline has 43 drugs in development by companies and five by universities/ institutes. Some of the companies in the Neuromyelitis Optica (Devic’s Syndrome) pipeline products market are: SinoMab Bioscience, BRL Medicine and Tasly Biopharmaceuticals.
The key targets in the Neuromyelitis Optica (Devic’s Syndrome) pipeline products market include B Lymphocyte Antigen CD20, Complement C5, and B Lymphocyte Antigen CD19.
The key mechanisms of action in the Neuromyelitis Optica (Devic’s Syndrome) pipeline product include B Lymphocyte Antigen CD20 Inhibitor with six drugs in Phase III. The Neuromyelitis Optica (Devic’s Syndrome) pipeline products include seven routes of administration with the top ROA being Intravenous and seven key molecule types in the Neuromyelitis Optica (Devic’s Syndrome) pipeline products market including Monoclonal Antibody, and Small Molecule.
Neuromyelitis Optica (Devic’s Syndrome) overview
Neuromyelitis optica (NMO), also known as Devic’s syndrome, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord, or nerves. NMO is an autoimmune condition where the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness, and bladder/bowel problems.
For a complete picture of Neuromyelitis Optica (Devic’s Syndrome)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
